Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Conditions
Interventions
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
+1 more
Locations
43
United States
Huntsville, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Long Beach, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Start Date
February 4, 2015
Primary Completion Date
April 24, 2016
Completion Date
July 19, 2016
Last Updated
March 13, 2025
NCT07089121
NCT07151521
NCT06986018
NCT02994927
NCT02108860
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions